Logo

Aadi Bioscience’s Fyarro Receives US FDA’s Approval for the Treatment of Malignant Perivascular Epithelioid Cell Tumor

Share this

Aadi Bioscience’s Fyarro Receives US FDA’s Approval for the Treatment of Malignant Perivascular Epithelioid Cell Tumor

Shots:

  • The approval is based on the P-II (AMPECT) trial to evaluate the efficacy of Fyarro (IV) in 34 adults aged ≥18yrs. with LA unresectable or metastatic malignant PEComa
  • The results showed ORR (39%) as assessed by independent review & 2 patients achieved a CR after prolonged follow up; m-DoR has not been reached with a median follow-up of 36 mos., 92% & 67% had a response through ≥6 & ≥12mos. & 58% had a response through ≥2yrs.
  • Fyarro is an mTOR inhibitor & the 1st approved therapy indicated for advanced malignant in adults. The company plans to launch Fyarro in Q1’22

Ref: Aadi Bioscience | Image: Aadi Bioscience

Click here to­ read the full press release 

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions